- Home
- Healthcare professionals
- ACE Technology Guidances
- Drug Guidance
- Dacomitinib for treating EGFR mutation-positive non-small-cell lung cancer
Drug guidance
Dacomitinib for treating EGFR mutation-positive non-small-cell lung cancer
Condition
Cancer
Respiratory
17 August 2021
Published on 27 Jul 2021
Last Updated on 17 Aug 2021
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
Dacomitinib 15 mg, 30 mg and 45 mg tablets for treating locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer.
Subsidy status
Dacomitinib 15 mg, 30 mg and 45 mg tablets are recommended for inclusion on the MOH Standard Drug List (SDL) with effect from 3 August 2021.
Dacomitinib for treating EGFR mutation-positive NSCLC (17 Aug 2021) [PDF, 142 KB]
Dacomitinib for treating EGFR mutation-positive NSCLC PES (27 Jul 2021) [PDF, 73 KB]